Zai Lab Limited reports developments for a commercial-stage biopharmaceutical company with American depositary shares traded under ZLAB and ordinary shares listed in Hong Kong. The company discovers, develops, licenses and commercializes therapies for oncology, immunology, neuroscience and infectious disease, with operations based in China and the United States.
Recurring company updates include financial results, regulatory designations, clinical and preclinical data, collaborations and product updates across programs such as zocilurtatug pelitecan, ZL-1503, ZL-6201 and ZL-1222. Updates also address regional commercial products and pipeline assets including ZEJULA, VYVGART, KarXT and TIVDAK.
Zai Lab Limited (NASDAQ: ZLAB) and Turning Point Therapeutics, Inc. (NASDAQ: TPTX) announced that the FDA granted a Breakthrough Therapy designation to their lead drug candidate, repotrectinib. This status is for treating advanced solid tumors with an NTRK gene fusion, particularly after prior treatments have failed. The designation aims to expedite the drug's development, indicating potential significant improvement over existing therapies. A Type B meeting with the FDA is planned to discuss next steps for registration, anticipated in the first half of 2022.
Zai Lab Limited (NASDAQ: ZLAB) and Novocure (NASDAQ: NVCR) announced the completion of patient enrollment in a phase 2 pilot trial focusing on the use of Tumor Treating Fields (TTFields) combined with chemotherapy for treating unresectable gastric adenocarcinoma. Conducted in Greater China, this trial aims to assess safety and efficacy, with final data collection expected in the first half of 2022. Gastric cancer poses a significant healthcare challenge in China, with a high incidence and low survival rates, underscoring the importance of this trial in addressing unmet medical needs.
Novocure (NASDAQ: NVCR) and Zai Lab (NASDAQ: ZLAB) announced the enrollment of the final patient in a phase 2 pilot trial targeting gastric adenocarcinoma. This trial investigates the safety and efficacy of Tumor Treating Fields (TTFields) in combination with XELOX chemotherapy as a first-line treatment. Approximately 30 patients have been enrolled, with final data collection expected in the first half of 2022. Gastric cancer poses a significant health threat in China, highlighting the unmet medical need. Results from this trial may influence future treatment options in the region.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) recently conducted a Virtual R&D Day, outlining its growth strategy and product pipeline. The company anticipates having over 15 marketed products across more than 35 indications by 2025. Key presentations highlighted Zai Lab's focus on oncology, autoimmune disorders, and infectious diseases, particularly addressing significant unmet needs in lung and gastrointestinal cancers in China. Their commercial ambitions aim for leadership in the Chinese market, with plans for ten additional product launches in the near term.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced plans to expand its operations in the U.S. by establishing a new office in Cambridge, focusing on alliance management, business development, legal, and governance functions. This strategic move aims to solidify its presence in a key biotechnology hub. CEO Dr. Samantha Du emphasized the importance of collaboration in enhancing healthcare. The company will also host a Global R&D Day on September 22 to showcase its innovative pipeline and growth potential to global investors.
Zai Lab Limited announced on September 14, 2021, that its investigational drug bemarituzumab received Breakthrough Therapy Designation from the CDE of the NMPA. This therapy targets patients with FGFR2b overexpressing and HER2-negative metastatic gastric and gastroesophageal (GEJ) cancers, in combination with modified FOLFOX6 chemotherapy. The Phase 2 FIGHT study showed significant clinical benefits for bemarituzumab, achieving statistical significance in progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). This drug aims to address a considerable healthcare need in China.
Zai Lab Limited (NASDAQ: ZLAB) announced a Virtual R&D Day for analysts and investors on September 22, 2021, from 8:30 a.m. to 11:30 a.m. EDT. The event will feature a live Q&A session and requires prior registration. Participants will receive login and dial-in details upon registration. This event highlights Zai Lab's commitment to addressing unmet medical needs through innovative therapies in oncology, autoimmune disorders, and infectious diseases. An archived replay will be available post-webcast.
Zhongchao Inc. (NASDAQ: ZCMD) has expanded its patient management services for ovarian cancer through its subsidiary, Shanghai Zhongxin Medical Technology. This follows the Zeyoulexiang Patient Assistance Project, which aids patients requiring Niraparib. Utilizing their All-in-One System, over 5,000 patients have benefited since July 2021. The ovarian cancer market is projected to grow significantly, from $1.8 billion in 2018 to $6.7 billion by 2028. Zhongchao aims to capitalize on this growth by enhancing treatment outcomes and expanding its patient management operations.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced its participation in two upcoming virtual investor conferences in September 2021. The Jefferies Asia Forum will be held on September 8 at 7:00 p.m. HKT, followed by a Fireside Chat at Citi’s 16th Annual BioPharma Virtual Conference on September 10 at 11:35 a.m. EDT. Live webcasts will be accessible under the "Events & Presentations" section of Zai Lab's website, with an archive available for 90 days post-event. Zai Lab focuses on innovative therapies in oncology, autoimmune disorders, and infectious diseases.
Zai Lab Limited (NASDAQ: ZLAB) announced a strong performance in Q2 2021, achieving net product revenues of $36.9 million, up from $11.0 million year-over-year. Key growth drivers included ZEJULA ($23.4 million) and Optune ($9.5 million). The company launched QINLOCK in China and entered strategic partnerships with Mirati and MacroGenics. Despite a net loss of $163.3 million, driven by R&D expenses ($142.2 million), Zai Lab's cash reserves stood at $1.77 billion as of June 30, 2021. Anticipated regulatory milestones include NUZYRA's approval and other significant data readouts.